Monograph
J07BG01 - Rabies, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the rabies, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated rabies virus.
Therapeutic characteristics
The rabies vaccine is indicated for pre-exposure and post-exposure prophylaxis against rabies. It is administered intramuscular according to a three or five dose schedule.
Metabolism and pharmacokinetics
The rabies vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Rabipur. (Last edition: 03.12. 2015).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Finland© NAPOS 2024